Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin for VTE Prevention in Pregnancy
NCT00878826Phase 3Completed
- Sponsor
- Stanford University
- Start
- May 2009
- Primary completion
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of enoxaparin in venous thromboembolism (VTE) (3 arms), sponsored by Stanford University. Primary endpoint: Peak Anti-Xa Level. Started May 2009; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00878826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00878826.